Shares of Lupin were trading higher for the sixth straight day, up 3.3 per cent to Rs 854, on the BSE on Wednesday in the intra-day deals after the company’s Mandideep Unit II facility received Establishment Inspection Report (EIR) from the US health regulator.
The stock of the drug maker has rallied 47 per cent in the past six trading days, and was quoting close to its 52-week high level of Rs 882 touched on May 2, 2019.
"The company has received the Establishment Inspection Report (EIR) after the closure of the US Food and Drug Administration (USFDA) inspection
"The company has received the Establishment Inspection Report (EIR) after the closure of the US Food and Drug Administration (USFDA) inspection